OBJECTIVE: Determine the multiparametric magnetic resonance imaging (mpMRI) appearance of the prostate following focal laser ablation (FLA) for PCa and to identify imaging characteristics associated with recurrent disease. METHODS: Retrospective analysis of patients who underwent FLA for low-intermediate risk PCa between 2010 and 2014 was performed. Early (median 4 months) and late mpMRI (median 49 months) follow-up were qualitatively assessed for T2-weighted, dynamic contrast enhanced (DCE) and diffusion weighted imaging (DWI) appearances and also compared to corresponding PSA values and biopsy results. RESULTS: 55 cancers were treated in 54 men (mean age 61.0 years). Early mpMRI was performed in 30 (54.5%) patients while late follow-up mpMRI in 42 (84%). Ill-defined scarring with and without atrophy at the treatment site were the most common appearances. In patients with paired MRI and biopsy, one of four patients with clinically significant PCa on biopsy (≥GG2 or≥6 mm GG1) showed hyperenhancement or restricted diffusion at early follow-up. At late follow-up, positive biopsies were seen in 5/8 (63%) cases with hyperenhancement and 5/6 (83%) cases with restricted diffusion at the treatment site. PSA change was not associated with biopsy results at either time point. CONCLUSION: mpMRI is able to document the morphological and temporal changes following focal therapy. It has limited ability to detect recurrent disease in early months following treatment. Late-term mpMRI is sensitive at identifying patients with recurrent disease. Small sample size is, however, a limitation of the study. ADVANCES IN KNOWLEDGE: Implementing MRI in follow-up after FT may be useful in predicting residual or recurrent PCa and therefore provide reliable outcome data.
OBJECTIVE: Determine the multiparametric magnetic resonance imaging (mpMRI) appearance of the prostate following focal laser ablation (FLA) for PCa and to identify imaging characteristics associated with recurrent disease. METHODS: Retrospective analysis of patients who underwent FLA for low-intermediate risk PCa between 2010 and 2014 was performed. Early (median 4 months) and late mpMRI (median 49 months) follow-up were qualitatively assessed for T2-weighted, dynamic contrast enhanced (DCE) and diffusion weighted imaging (DWI) appearances and also compared to corresponding PSA values and biopsy results. RESULTS: 55 cancers were treated in 54 men (mean age 61.0 years). Early mpMRI was performed in 30 (54.5%) patients while late follow-up mpMRI in 42 (84%). Ill-defined scarring with and without atrophy at the treatment site were the most common appearances. In patients with paired MRI and biopsy, one of four patients with clinically significant PCa on biopsy (≥GG2 or≥6 mm GG1) showed hyperenhancement or restricted diffusion at early follow-up. At late follow-up, positive biopsies were seen in 5/8 (63%) cases with hyperenhancement and 5/6 (83%) cases with restricted diffusion at the treatment site. PSA change was not associated with biopsy results at either time point. CONCLUSION: mpMRI is able to document the morphological and temporal changes following focal therapy. It has limited ability to detect recurrent disease in early months following treatment. Late-term mpMRI is sensitive at identifying patients with recurrent disease. Small sample size is, however, a limitation of the study. ADVANCES IN KNOWLEDGE: Implementing MRI in follow-up after FT may be useful in predicting residual or recurrent PCa and therefore provide reliable outcome data.
Authors: Pieter J De Visschere; Gert O De Meerleer; Jurgen J Fütterer; Geert M Villeirs Journal: AJR Am J Roentgenol Date: 2010-06 Impact factor: 3.959
Authors: Philipp M Huber; Naveed Afzal; Manit Arya; Silvan Boxler; Tim Dudderidge; Mark Emberton; Stephanie Guillaumier; Richard G Hindley; Feargus Hosking-Jervis; Lucas Leemann; Henry Lewi; Neil McCartan; Caroline M Moore; Raj Nigam; Chris Odgen; Raj Persad; George N Thalmann; Jaspal Virdi; Mathias Winkler; Hashim U Ahmed Journal: J Urol Date: 2020-01-13 Impact factor: 7.450
Authors: Kae Jack Tay; Mahul B Amin; Sangeet Ghai; Rafael E Jimenez; James G Kench; Laurence Klotz; Rodolfo Montironi; Satoru Muto; Ardeshir R Rastinehad; Baris Turkbey; Arnauld Villers; Thomas J Polascik Journal: World J Urol Date: 2018-06-09 Impact factor: 4.226
Authors: Eric Walser; Anne Nance; Leslie Ynalvez; Shan Yong; Jacqueline S Aoughsten; Eduardo J Eyzaguirre; Stephen B Williams Journal: J Vasc Interv Radiol Date: 2019-03 Impact factor: 3.464
Authors: Jeremy Cepek; Blaine A Chronik; Uri Lindner; John Trachtenberg; Sean R H Davidson; Jeffrey Bax; Aaron Fenster Journal: Med Phys Date: 2013-01 Impact factor: 4.071
Authors: B G Muller; W van den Bos; M Brausi; J J Fütterer; S Ghai; P A Pinto; I V Popeneciu; T M de Reijke; C Robertson; J J M C H de la Rosette; S Scionti; B Turkbey; H Wijkstra; O Ukimura; T J Polascik Journal: World J Urol Date: 2015-01-06 Impact factor: 4.226
Authors: Aytekin Oto; Ila Sethi; Gregory Karczmar; Roger McNichols; Marko K Ivancevic; Walter M Stadler; Sydeaka Watson; Scott Eggener Journal: Radiology Date: 2013-02-25 Impact factor: 11.105
Authors: Louise Dickinson; Hashim U Ahmed; Richard G Hindley; Neil McCartan; Alex Freeman; Clare Allen; Mark Emberton; Alex P Kirkham Journal: Urol Oncol Date: 2016-09-20 Impact factor: 3.498
Authors: Massimo Valerio; Hashim U Ahmed; Mark Emberton; Nathan Lawrentschuk; Massimo Lazzeri; Rodolfo Montironi; Paul L Nguyen; John Trachtenberg; Thomas J Polascik Journal: Eur Urol Date: 2013-06-06 Impact factor: 20.096